PledPharma

Interim report January-September 2017



CONTENTS

SUMMARY

Q3 IN BRIEF

- PledPharma established a scientific advisory board for the PledOx® program and conducted its first meeting.
- The dialogue with EMA regarding the design of the PledOx® clinical program is in the final stage
- A collaboration with a contract research organization has been initiated for the execution of the PledOx® clinical program
- PledPharma recruited Stefan Carlsson as new Chief Medical Officer
- Approval from Data Safety and Monitoring Board for start of recruitment in the second cohort in the Proof of Principle study with Aladote®

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

- Calmangafodipir as a potential new treatment of acute liver failure is presented at a conference on liver disease
- Dosage of patients has been initiated in the second dose group in the Proof of Principle study with Aladote®

FINANCIALS

- Quarterly result MSEK -27,3 (-7,9)
- Cash MSEK 354,3 (23,6)
- Cash flow from operating activities MSEK -9,4 (-8,1)
- Result per share SEK -0,6 (-0,3)

JAN-SEPT IN BRIEF

- Nicklas Westerholm was recruited as the new CEO for PledPharma
- Christian Sonesson was recruited as Vice President Product Strategy and Development
- Gunilla Osswald, Elisabeth Svanberg and Marie Ekström Trägårdh were elected to the Board of Directors.
- PledPharma received advice from the FDA for the continued development of PledOx® and is now following up with the EMA for the implementation of a global clinical program.
- PledPharma's key patent application for the active pharmaceutical ingredient of the drug candidates PledOx® and Aladote® was approved in Japan, Russia and China (earlier approved in the US).
- Patent for the anticancer-effect of PLED compounds was approved in Canada and an important use patent for PLED compounds was approved in Israel.
- PledPharma started a clinical study with drug candidate Aladote®.

FINANCIALS

- Result for the period MSEK -55,8 (-26,8)
- Cash MSEK 354,3 (23,6)
- Cash flow from operating activities MSEK -39,7 (-26,8)
- Result per share SEK-1,1 (-0,9)
- A warrants program was established

FINANCIAL SUMMARY

	2017 July-Sept	2016 July-Sept	2017 Jan-Sept	2016 Jan-Sept	2016 Jan-Dec
Result after tax, KSEK	-27 338	-7 932	-55 807	-26 761	-38 223
Cash flow, KSEK	-9 406	-8 075	-39 656	-26 770	343 638
Cash, KSEK	354 342	23 590	354 342	23 590	393 998
Equity ratio %	94%	82%	94%	82%	98%
Result per share, SEK	-0,6	-0,3	-1,1	-0,9	-1,3
Result per share after dilution, SEK	-0,6	-0,3	-1,1	-0,9	-1,3
Number of employees	6	4	6	4	4

COMMENTS FROM THE CEO

PledPharma has during the quarter continued its focus on finalizing the design of the clinical development program for PledOx®, our unique drug candidate for preventing chemotherapy induced nerve damage. At the same time, we continue to see good progress in our ongoing clinical trial with Aladote®.

PledOx® - constructive dialogue with EMA
The dialogue with the European Regulatory Authority EMA regarding the design of the continued clinical development for PledOx® remains constructive and is in its final stage. The discussion has been supported by the expertise we have gathered from our newly established Scientific Advisory Board, which consists of five renowned international experts in the fields of oncology, neurology and patient-reported evaluation.

Work has progressed so that we, following a thorough procurement, have entered a collaboration with an international contract research organization (CRO) as we strive for a rapid initiation of the remaining clinical studies after the regulatory discussion with the EMA has been finalized. Therefore, we see project start-up costs flowing through the quarter.

Aladote® study proceeding well, the second patient cohort has now started
During the quarter, we have taken clear steps forward in the development of Aladote®, a drug candidate developed to prevent liver damage associated with paracetamol poisoning(overdose). After completing the dosing of the first 8 patients DSMB gave approval to start the next group, the second patient cohort, in the proof of principle study conducted in Scotland under the leadership of a leading expert in the field, Dr James Dear. In addition, Dr Dear will present the preclinical study which served as a base for the ongoing clinical study, as well as in-depth information on the clinical study's design at the American Association for the Study of Liver Diseases (AASLD).

PledPharma strengthens the organization and its capabilities
In August, Dr. Christian Sonesson took over the position of Vice President Product &

Strategy Development and on October 30, we welcome our new Chief Medical Officer, Dr. Stefan Carlsson. Christian and Stefan brings valuable expertise and experience in their respective areas of responsibility. The recruitments, which have increased staff costs for the company, are important in ensuring the expertise to continue to drive PledPharma's development programs and will to a certain extent be mitigated with reduced costs for external consultants.

We have important milestones, with value-added potential in front of us and expect soon to present a well-founded plan for the continued clinical development of PledOx®, based on our interactions with regulatory agencies and our scientific advisory board. By the beginning of 2018, we expect the results from the clinical trial with Aladote®.

Nicklas Westerholm
CEO

PLEDPHARMA IN BRIEF

PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose.

The company's most advanced project **PledOx®** is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development.

The drug candidate **Aladote®** is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning.

PledPharma (STO:PLED) is listed on Nasdaq First North.

For further information, please contact:
Nicklas Westerholm, VD
Phone: +46 73-354 20 62
e-mail: nicklas.westerholm@pledpharma.se

PledPharma AB (publ)
Grev Turegatan 11c, 114 46 Stockholm
Phone: +46 8-679 72 10
www.pledpharma.se

PROJECT UPDATES

PLEDOX®

PLEDOX® IN BRIEF

PledOx® is a “first in class” drug candidate developed to provide patients, that are treated adjuvantly or for metastatic colorectal cancer, prevention against the nerve damage that can occur in conjunction with chemotherapy treatment. The side-effects of chemotherapy can lead to a reduction of the planned dose or in worst case, treatment discontinuation. Unfortunately, it appears that the chemotherapy can induce permanent nerve damage. Patients may, for example, experience discomfort and numbness in the hands and feet, difficulty with balance with risk of falling and problems with sensation that can last for the rest of their lives.

The results from the Phase IIb study PLIANT, where patients with metastatic colorectal cancer were treated with the chemotherapy combination FOLFOX and PledOx® (calmangafodipir), indicates that the patients who received PledOx® had a lower risk than the placebo group to suffer from nerve damage during the chemotherapy.

The presence of the investigator reported sensory nerve damage, the primary endpoint, was after treatment 43 percent lower in the group of patients treated with PledOx® compared with the placebo group (p = 0.14). This was not statistically significant, but a difference of this magnitude is considered to be clinically relevant. No apparent negative effect on the efficacy of the cancer treatment was observed. Furthermore, there was a coherence between investigator reported sensory nerve damage and the different patient reported evaluations made, which is valuable for future studies.

Post hoc analyzes on patient-reported neuropathy show a statistically significant reduction in the incidence and intensity of the symptoms of nerve damage in comparison with placebo. Additionally, it was noted that the investigator-reported symptoms of neuropathy occur later and disappear faster after pretreatment with PledOx®.

During the follow-up after completion of chemotherapy, the patient-reported incidence and intensity of neuropathy was statistically significantly lower in patients pretreated with PledOx®. The severity of neuropathy was 62 percent lower 12 weeks after discontinuation of treatment in the group of patients treated with PledOx® versus placebo (p <0.05) and at 24 weeks the corresponding difference between PledOx® and placebo group was 75 percent (p <0, 01).

PledPharma is preparing to initiate the remaining clinical trials with PledOx® in 2017.

EVENTS DURING THE QUARTER

In the third quarter, intensive work has been ongoing to prepare for the start of the upcoming clinical trials with PledOx® and the dialogue with the European Medicines Agency EMA regarding the design of the studies is in its final stages.

In August, a scientific advisory board (SAB) was established for the continued clinical development of PledOx® and a first meeting was conducted in September which gave PledPharma valuable views and input on the design of the remaining clinical trial program and the regulatory strategy for PledOx®. With the combined expertise within the group PledPharma aim at maximizing the potential for market approval and optimizing the commercial potential of the drug candidate. The SAB consists of the following internationally leading experts in oncology (Professor Emeritus Bengt Glimelius, Sweden), Neurology (Professor Guido Cavaletti, Italy), Chronic Pain (Professor Rolf Karlsten, Sweden) and Methods for Measuring Patients' Quality of Life (Professor David Cella, USA) and a non-named leading international expert from the United States in the field of chemotherapy induced peripheral neuropathy. During the quarter, PledPharma has initiated collaboration with an international CRO (contract research organization) for upcoming clinical studies with PledOx®.

ALADOTE®

ALADOTE® IN BRIEF

Aladote® is being developed to counter the onset of acute liver failure caused by paracetamol (acetaminophen) poisoning. Paracetamol is one of the most commonly used drugs in both deliberate and accidental overdoses. High concentrations of paracetamol breaking down in the liver can lead to acute liver failure, and even death. The current treatment for paracetamol poisoning (N-acetylcysteine) is effective if the patient seeks medical care within 8 hours of ingestion. However, there is currently no well-functioning treatment for patients who arrive more than 8 hours after ingestion.

Preclinical studies have shown that Aladote® was effective in animal models for a much longer period than N-acetylcysteine (NAC). Aladote® is a "first-in-class" treatment and there is a large medical need as there are currently no adequate treatment for patients that arrive late to the hospital after an overdose of acetaminophen. An Aladote® safety and tolerability study has begun at the Edinburgh Royal Infirmary. This is the first time that Aladote® is tested in patients who overdose paracetamol.
The trial is being led by Dr James Dear, Reader in Pharmacology at the University of Edinburgh.

EVENTS DURING THE QUARTER

During the quarter, the proof of principle study in patients with acetaminophen poisoning continued at Edinburgh Royal Infirmary and the DSMB (Data and Safety Monitoring Board) gave approval to proceed recruitment to patient cohort two. After the end of the quarter, 10 patients out of a total of 24 patients have completed their treatment in the study in which safety and tolerability are tested. An abstract of preclinical data for calmangafodipir will be presented by the study's lead investigator Dr James Dear at the American Association for the Study of Liver Diseases (AASLD) International Conference in Washington DC, October 22, 2017.

FINANCIAL INFORMATION

THIRD QUARTER AND THE PERIOD
JANUARY – SEPTEMBER 2017

REVENUE, EXPENSES AND RESULTS

Revenues

Revenue amounted to KSEK 77 (40) during the quarter and to KSEK 278 (985) for the period. The revenue consisted of foreign exchange gains. The difference between the periods 2016 and 2017 is explained by a retroactive price adjustment of KSEK 839 in the PLIANT study during the second quarter of 2016. Interest income amounted to KSEK 41 (32) for the quarter and to KSEK 122 (106) for the period.

Expenses

Operating expenses amounted to KSEK 27 456 (8 004) for the quarter and to KSEK 56 207 (27 853) for the period. Of these, planned project costs amounted to KSEK 20 366 (3 717) for the quarter and to KSEK 38 097 (13 142) for the period. The increase compared to the previous year is largely due to start-up costs for the contract research organization for the forthcoming clinical studies with PledOx®, which amounted to KSEK 16 099.

Employee costs amounted to KSEK 3 253 (1 443) for the quarter and to KSEK 7 252 (4 631) for the period. The increase is due to recruitment costs and salaries for new employees. Other operating costs amounted to KSEK 3 813 (2 809) for the quarter and to KSEK 10 720 (9 793) for the period and included costs of license patents and consulting costs. Depreciation amounted to KSEK 0 (0) for the periods.

Results

Operating result amounted to KSEK -27 379 (-7 964) for the quarter and to KSEK -55 929 (-26 868) for the period. Result after financial items amounted to KSEK -27 338 (-7 932) for the quarter and to KSEK -55 807 (-26 761) for the period. No income tax was reported for the periods (-). Result per average share before and after dilution amounted to SEK -0,6 (-0.3) for the quarter and to SEK -1,1 (-0,9) for the period.

FINANCIAL POSITION

Cash

Cash at September 30, 2017 amounted to KSEK 354 342 (23 590).

Cash flow

Cash flow from operating activities amounted to KSEK -9 599 (-8 075) for the quarter and to -41 174 (-26 770) for the period. The cash flow from investment activities amounted to KSEK 0 (0). Cash flow from financial activities amounted to KSEK 193 (0) and relates to the issue of warrants for the employees. Cash flow amounted to KSEK -9 406 (-8 075) for the quarter and to KSEK -39 656 (-26 770) for the period.

Equity and equity ratio

At September 30, 2017 equity amounted to KSEK 335 273 (21 271). Shareholders' equity per share amounted to SEK 6.9 (0.7), at the end of the period. The company's equity ratio was 94 (82) %.

Debts

No long-term debts were outstanding (-). Current liabilities amounted to KSEK 21 958 (4 769) and consisted mainly of accounts payables relating CRO costs for the start-up of clinical studies.

INVESTMENTS, TANGIBLE AND INTANGIBLE ASSETS

During the period, investments in tangible fixed assets corresponding to KSEK 0 (0).

SHARE

The number of shares at September 30, 2017 were 48 666 656. PledPharma´s shares are listed on Nasdaq First North since 7 April 2011.

WARRANT PROGRAM

The Annual General Meeting 2017 resolved on a warrants program for employees and board members of PledPharma of 2,306,000 warrants, each warrants entitling the holder to subscribe for one (1) new share in the company at a subscription price of SEK 26 per share. At full utilization of all options, the company's shares will be increased by 2,306,000 to 50,972,656. As of September 30, 2017, 1,326 500 warrants had been subscribed for by employees and board members of PledPharma.

EMPLOYEES

Number of employees as of September 30, 2017 was 6 (4) persons, 3 women and 3 men.

PARENT COMPANY

The parent company's expenses for the quarter amounted to KSEK 27 456 (8 004) and to KSEK 56 207 (27 853) for the period.

The parent company's result after financial items amounted to KSEK -27 338 (-7 932) for the quarter and to KSEK -55 807 (-26 761) for the period.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

SEKk	2017 July -Sept	2016 July -Sept	2017 Jan-Sept	2016 Jan-Sept	2016 Jan - Dec
Revenue					
Other operating income	77	40	278	985	1 026
	77	**40**	**278**	**985**	**1 026**
Operating expenses					
Project costs	-20 366	-3 717	-38 097	-13 142	-19 513
Other external costs	-3 813	-2 809	-10 720	-9 793	-13 162
Employee benefit costs	-3 253	-1 443	-7 252	-4 631	-6 357
Depreciation and impairment, fixed assets	0	0	0	0	0
Other operating expenses	-23	-34	-138	-287	-356
Operating result	**-27 379**	**-7 964**	**-55 929**	**-26 868**	**-38 363**
Net financial items					
Interest income	41	32	122	106	140
Interest expense and similar items	-	-	-	-	-
Result after financial net	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Result before tax	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Tax	-	-	-	-	-
Result after tax	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Statement of comprehensive income					
Other comprehensive income	-	-	-	-	-
Comprehensive income for the period	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Net earnings and comprehensive income is entirely attributable to parent company shareholders					
Share Data					
Number of shares at the end of period	48 666 656	28 388 883	48 666 656	28 388 883	48 666 656
Average number of shares during period	48 666 656	28 388 883	48 666 656	28 388 883	29 675 504
Result per share before dilution (SEK)	-0,6	-0,3	-1,1	-0,9	-1,3
Result per share after dilution (SEK)	-0,6	-0,3	-1,1	-0,9	-1,3
Equity per share (SEK)	6,9	0,7	6,9	0,7	8,0
Equity per share after dilution (SEK)	6,6	0,7	6,6	0,7	8,0

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEKk	2017-09-30	2016-09-30	2016-12-31
ASSETS			
Fixed assets			
Property, plant and equipment			
Equipment, tools, fixtures and fittings	0	0	0
Total fixed assets	0	0	0
Current assets			
Current receivables			
Other receivables	411	405	1 344
Prepaid expenses and accrued income	2 477	2 044	1 093
	2 888	2 449	2 437
Cash and bank balances	354 342	23 590	393 998
Total current assets	**357 230**	**26 040**	**396 435**
Total assets	**357 230**	**26 040**	**396 435**
EQUITY AND LIABILITIES			
Equity			
Share capital	2 561	1 494	2 561
Other capital contributions	388 518	46 538	425 224
Accumulated loss including net loss	(55 807)	(26 761)	(38 223)
Total equity	**335 273**	**21 271**	**389 562**
Short term liabilities			
Accounts payable	19 023	2 271	4 678
Tax liabilities	-	-	-
Other liabilities	691	202	213
Accrued expenses and deferred income	2 244	2 295	1 983
Total short term liabilities	**21 958**	**4 769**	**6 873**
Total equity and liabilities	**357 230**	**26 040**	**396 435**

CONSOLIDATED STATEMENT OF CASH FLOWS

SEKk	2017 July -Sept	2016 July -Sept	2017 Jan - Sept	2016 Jan - Sept	2016 Jan-Dec
OPERATING ACTIVITIES					
Result after financial net	-27 338	-7 932	-55 807	-26 761	-38 223
Adjustments for non-cash items	0	0	0	0	0
Tax paid	0	0	0	0	0
Cash flow from operating activities before changes in working capital	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Changes in short term liabilities	1 367	7 109	-451	-448	-436
Changes in account payables	15 485	-7 178	14 345	505	2 912
Changes in operating liabilities	887	-74	740	-66	-367
Cash flow from operating activities	**-9 599**	**-8 075**	**-41 174**	**-26 770**	**-36 114**
INVESTING ACTIVITIES					
Cash flow from investing activities	**-**	**-**	**-**	**-**	**-**
FINANCING ACTIVITIES					
New share issue	194	-	1 518	-	405 555
Cost new share issue	-	-	-	-	(25 803)
Cash flow from financing activities	**194**	**-**	**1 518**	**-**	**379 753**
Cash flow for the period					
Balance at beginning of period	363 748	31 666	393 998	50 360	50 360
Change in cash	-9 406	-8 075	-39 656	-26 770	343 638
CASH BALANCE AT THE END OF THE PERIOD	354 342	23 590	354 342	23 590	393 998

CONSOLIDATES STATEMENT OF CHANGES IN EQUITY

kSEK	Share capital	Other capital contributions	Accumulated loss incl. net result for the period	Totalt equity
Opening balance 20160101	**1 494**	**90 374**	**(43 836)**	**48 032**
Loss allocation according to AGM	-	(43 836)	43 836	-
Comprehensive income for period	-	-	(26 761)	(26 761)
Closing balance 20160930	**1 494**	**46 538**	**(26 761)**	**21 271**
Opening balance 20170101	**2 561**	**425 224**	**(38 223)**	**389 562**
Loss allocation according to AGM	-	(38 223)	38 223	-
Issue of warrants	-	1 518	-	-
Comprehensive income for period	-	-	(55 807)	(55 807)
Closing balance 20170930	**2 561**	**388 518**	**(55 807)**	**335 273**
Opening balance 20160101	**1 494**	**90 374**	**(43 836)**	**48 032**
Loss allocation according to AGM	-	(43 836)	43 836	-
New share issue	1 067	404 488	-	405 555
Costs new share issue	-	(25 803)	-	(25 803)
Comprehensive income for period	-	-	(38 223)	(38 223)
Closing balance 20161231	**2 561**	**425 224**	**(38 223)**	**389 562**

CONSOLIDATED KEY RATIOS

The key ratios below are useful to those who read the financial statements and a complement to other performance targets in evaluating strategic investment implementation and the Group's ability to achieve financial goals and commitments.

KSEK	2017 July -Sept	2016 July -Sept	2017 Jan-Sept	2016 Jan-Sept	2016 Jan - Dec
Equity	335 273	21 271	335 273	21 271	389 562
Equity ratio %	94%	82%	94%	82%	98%
Return on equity %	neg.	neg.	neg.	neg.	neg.
Number of shares at the end of the period	48 666 656	28 388 883	48 666 656	28 388 883	48 666 656
Number of shares at the end of the period after dilution	50 972 656	28 388 883	50 972 656	28 388 883	48 666 656
Average number of shares under the period	48 666 656	28 388 883	48 666 656	28 388 883	29 675 504
Average number of shares under the period after dilution	50 972 656	28 388 883	50 972 656	28 388 883	29 675 504
Share Data					
Result per share	-0,6	-0,3	-1,1	-0,9	-1,3
Result per share after dilution*	-0,6	-0,3	-1,1	-0,9	-1,3
Cash flow from operating activities	-0,2	-0,3	-0,8	-0,9	-1,2
Equity per share	6,9	0,7	6,9	0,7	8,0
Equity per share after dilution	6,6	0,7	6,6	0,7	8,0
Dividend	-	-	-	-	-
Number of employees	6	4	6	4	4

*Effect from dilution is not considered when result is negative.

KEY RATIOS DEFINITIONS

Ratios that have been calculated according to IFRS

Earnings per share
Net income divided by average number of shares before dilution

Number of shares at end of period
The number of outstanding shares before dilution at the end of the period

Number of shares after dilution
The number of issued shares after dilution effect of potential shares at end of period

Average number of shares during the period
Average number of outstanding shares before dilution for the period

Average number of shares during the period after dilution
Average number of issued shares after dilution effect of potential shares

Number of employees (average)
The average number of employees at the end of each period

Ratios that have not been calculated in accordance with IFRS

Equity ratio, %
The company defines the ratio as follows; The period's closing equity divided by the period's closing balance sheet. The company uses the alternate ratio Equity as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the company's capital structure.

Return on equity, %
The company defines the ratio as follows; Net income divided by shareholders' equity. The company uses the alternate key figure Return on equity, % because the company believes that the key ratio gives investors a better understanding of the return generated on the total capital that the shareholders have invested in the Company.

Cash flow from operations per share
The company defines the ratio as follows; Cash flow from operating activities divided by the number of shares outstanding at the end of the period. The company uses the alternate key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.

Equity per share
The company defines the ratio as follows; Equity divided by number of shares outstanding at the end of the period. The company uses the alternate key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.

PARENT COMPANY - INCOME STATEMENT

SEKk	2017 July -Sept	2016 July -Sept	2017 Jan-Sept	2016 Jan-Sept	2016 Jan - Dec
Revenue					
Other operating income	77	40	278	985	1 026
	77	**40**	**278**	**985**	**1 026**
Operating expenses					
Project costs	-20 366	-3 717	-38 097	-13 142	-19 513
Other external costs	-3 813	-2 809	-10 720	-9 793	-13 162
Employee benefit costs	-3 253	-1 443	-7 252	-4 631	-6 357
Depreciation and impairment, fixed assets	0	0	0	0	0
Other operating expenses	-23	-34	-138	-287	-356
Operating result	**-27 379**	**-7 964**	**-55 929**	**-26 868**	**-38 363**
Net financial items					
Interest income	41	32	122	106	140
Interest expense and similar items	-	-	-	-	-
Result after financial net	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Result before tax	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**
Tax	-	-	-	-	-
Result after tax	**-27 338**	**-7 932**	**-55 807**	**-26 761**	**-38 223**

PARENT COMPANY - BALANCE SHEET

SEKk	2017-09-30	2016-09-30	2016-12-31
ASSETS			
Fixed assets			
Property, plant and equipment			
Equipment, tools, fixtures and fittings	0	0	0
Financial assets			
Shares and participations in group companies	50	50	50
Total fixed assets	**50**	**50**	**50**
Current assets			
Current receivables			
Other receivables	411	405	1 344
Prepaid expenses and accrued income	2 477	2 044	1 093
	2 888	2 449	2 437
Cash and bank balances	352 824	23 590	393 998
Total current assets	**355 713**	**26 040**	**396 435**
Total assets	**355 763**	**26 090**	**396 485**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital			
	2 561	1 494	2 561
Non-restricted equity			
Share premium reserve	387 000	46 538	425 224
Result for the period	(55 807)	(26 761)	(38 223)
Total equity	**333 754**	**21 271**	**389 562**
Short term liabilities			
Debt to group company	50	50	50
Accounts payable	19 023	2 271	4 678
Tax liabilities	-	-	-
Other liabilities	691	202	213
Accrued expenses and deferred income	2 244	2 295	1 983
Total short term liabilities	**22 008**	**4 819**	**6 923**
Total equity and liabilities	**355 763**	**26 090**	**396 485**

NOTES

NOTE 1 - Accounting principles

PledPharma applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. The parent company's interim report is prepared in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. Applied accounting principles and calculation methods are the same as in the latest annual report for 2016.

NOTE 2 – Additional information

Other information in accordance with IAS 34.16A are found on pages before the income statement and statement of comprehensive income. Information on earnings, cash flow and financial position, see page 5. For events after the period, see page 1.

NOTE 3 – Financial assets and debts

Group 30 September 2017

The fair value and carrying value are shown in the table below:

	Account and loan receivables	Financial debts	Total carrying amount	Fair value
Accounts receivable	-	-	**-**	**-**
Accrued but not invoiced income	-	-	**-**	**-**
Cash	354 342	-	354 342	354 342
Total assets	**354 342**	**-**	**354 342**	**354 342**
Accounts payable	-	19 023	19 023	19 023
Other liabilities	-	-	**-**	**-**
Total debts	**-**	**19 023**	**19 023**	**19 023**

Group 31 December 2016

The fair value and carrying value are shown in the table below:

	Account and loan receivables	Financial debts	Total carrying amount	Fair value
Accounts receivable	-	-	**-**	**-**
Accrued but not invoiced income	-	-	**-**	**-**
Cash	393 998	-	393 998	393 998
Total assets	**393 998**	**-**	**393 998**	**393 998**
Accounts payable	-	4 678	4 678	4 678
Other liabilities	-	-	**-**	**-**
Total debts	**-**	**4 678**	**4 678**	**4 678**

Not 4 – Related parties transactions

No related party transactions have taken place during the period.

OTHER INFORMATION

Next reports

Year-end report 2017, 22 February 2018

This report, and further information is available on the website, www.pledpharma.se

This is a translation of the Swedish interim report that has not been reviewed by the company's auditor.

For further information contact:

Nicklas Westerholm, CEO
Phone: +46 73-354 20 62
E-mail: nicklas.westerholm@pledpharma.se

Michaela Gertz, CFO
Phone: +46 70-926 17 75
E-mail: michaela.gertz@pledpharma.se

This information is such information as PledPharma AB (publ) is obliged to disclose in accordance with EU market abuse regulation and the Securities Markets Act. The information was submitted, through the above contact persons, for publication on 20 October 2017 at 8.00 am (CET)

PledPharma AB (publ)
Grev Turegatan 11c, 114 46 Stockholm
Org.nr. 556706-6724
Phone: 08-679 72 10
www.pledpharma.se

Certified Adviser

The company´s Certified Advisor is Erik Penser Bank (phone +46 8 463 80 00).

Analysts who follow PledPharma

Redeye, Klas Palin.

CERTIFICATION

This report provides a true and fair overview of the company's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the company is exposed.

Stockholm, October 20, 2017

Håkan Åström	Gunilla Osswald	Elisabeth Svanberg
Chairman of the board	*Board member*	*Board member*
Sten Nilsson	Marie Ekström Trägårdh	Nicklas Westerholm
Board member	*Board member*	*CEO*